Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down before the market opened on Tuesday . The stock had previously closed at $21.01, but opened at $20.11. Ascentage Pharma Group International shares last traded at $20.70, with a volume of 606 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to data from MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Trading Down 4.1%

The stock’s 50 day moving average is $23.39 and its 200-day moving average is $26.07. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter. On average, equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the second quarter worth $391,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the third quarter worth $96,000. ABC Arbitrage SA bought a new stake in Ascentage Pharma Group International in the third quarter worth $204,000. UBS Group AG lifted its position in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International in the third quarter worth $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.